\-\ Texto\\:\\ \ \(0\)\
\-\ supraclavicular\\ vascular\\ mass\\ with\\ prominent\\ superficial\\ veins\\.\ \(0\)\
\-\ this\\ patient\\ was\\ treated\\ with\\ a\\ short\\ course\\ of\\ propranolol\\ with\\ marked\\ interval\\ decrease\\ in\\ the\\ size\\ of\\ the\\ lesion\\.\ \(0\)\
\-\ lobulated\\,\\ intensely\\ enhancing\\ mass\\ lesion\\ with\\ high\\ flow\\ intralesional\\ vessels\\.\ \(0\)\
\-\ capillary\\ hemangioma\ \(2\)\
\-\ \\â\\€\\¢\\ capillary\\ \\(infantile\\)\\ hemangioma\ \(0\)\
\-\ \\â\\€\\¢\\ venous\\ malformation\ \(0\)\
\-\ \\â\\€\\¢\\ sarcoma\\ \\(rhabdomyosarcoma\\,\\ extraosseous\\ ewings\\,\\ undifferentiated\\ sarcoma\\)\ \(0\)\
\-\ \\â\\€\\¢\\ plexiform\\ neurofibroma\ \(0\)\
\-\ \\â\\€\\¢\\ arteriovenous\\ malformation\ \(0\)\
\-\ 15\\ month\\ old\\ baby\\ girl\\ with\\ enlarging\\ right\\ supraclavicular\\ \\/\\ shoulder\\ mass\\.\ \(1\)\
\-\ infantile\\ hemangiomas\\ are\\ benign\\ neoplasms\\ of\\ endothelial\\ cells\\.\\ \\ they\\ are\\ the\\ most\\ common\\ childhood\\ tumor\\,\\ occurring\\ in\\ 12\\%\\ of\\ children\\.\\ \\ they\\ are\\ more\\ common\\ in\\ females\\,\\ whites\\,\\ premature\\ infants\\,\\ and\\ twins\\.\\ \\ \ \(0\)\
\-\ at\\ birth\\ these\\ lesions\\ can\\ be\\ small\\ and\\ inconspicuous\\,\\ with\\ 60\\%\\ absent\\ at\\ birth\\.\\ \\ the\\ natural\\ history\\ is\\ a\\ two\\ stage\\ process\\ of\\ proliferation\\ and\\ regression\\.\\ \\ the\\ typical\\ hemangioma\\ will\\ begin\\ to\\ involute\\ by\\ 10\\ months\\ of\\ age\\,\\ with\\ half\\ of\\ all\\ lesions\\ having\\ resolved\\ by\\ 5\\ years\\.\ \(0\)\
\-\ clinically\\,\\ hemangiomas\\ appear\\ as\\ erythematous\\ or\\ blanching\\ macules\\,\\ or\\ appear\\ as\\ a\\ small\\ telangiectasia\\.\\ \\ the\\ clinical\\ appearance\\ depends\\ upon\\ the\\ degree\\ of\\ dermal\\ involvement\\ and\\ lesion\\ depth\\.\\ \\ lesions\\ involving\\ the\\ skin\\ have\\ a\\ more\\ characteristic\\ strawberry\\ appearance\\.\\ \\ deeper\\ lesions\\ demonstrate\\ a\\ blue\\ appearance\\.\\ \\ \ \(0\)\
\-\ most\\ hemangiomas\\ are\\ generally\\ treated\\ conservatively\\.\\ corticosteroids\\ are\\ the\\ first\\ line\\ of\\ treatment\\ for\\ problematic\\ infantile\\ capillary\\ hemangiomas\\.\\ \\ other\\ options\\ include\\ interferon\\ alpha\\ and\\ vincristine\\.\\ \\ propranolol\\ has\\ also\\ been\\ observed\\ to\\ inhibit\\ growth\\.\\ while\\ the\\ mechanism\\ of\\ action\\ is\\ unclear\\,\\ potential\\ explanations\\ include\\ vasoconstriction\\;\\ down\\-regulation\\ of\\ the\\ raf\\-mitogen\\-activated\\ protein\\ kinase\\ pathway\\;\\ and\\ the\\ triggering\\ of\\ apoptosis\\ of\\ capillary\\ endothelial\\ cells\\.\\ \ \(0\)\
\-\ capillary\\ hemangiomas\\ can\\ develop\\ life\\ threatening\\ complications\\,\\ such\\ as\\ consumptive\\ coagulopathy\\,\\ compression\\ of\\ vital\\ structures\\,\\ and\\ bleeding\\ secondary\\ to\\ fissure\\ or\\ ulcer\\ formation\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ hemangiomas\\:\\ 0\\.08337007621473382\ \(0\)\
\-\ capillary\\:\\ 0\\.07886095282207267\ \(0\)\
\-\ propranolol\\:\\ 0\\.05526970798725077\ \(0\)\
\-\ infantile\\:\\ 0\\.05226415566719451\ \(0\)\
\-\ endothelial\\:\\ 0\\.03969035595096237\ \(0\)\
\-\ hemangioma\\:\\ 0\\.03590883526836097\ \(0\)\
\-\ supraclavicular\\:\\ 0\\.03297912452963689\ \(0\)\
\-\ lesions\\:\\ 0\\.028684144280174892\ \(0\)\
\-\ down\\-regulation\\:\\ 0\\.027634853993625384\ \(0\)\
\-\ raf\\-mitogen\\-activated\\:\\ 0\\.027634853993625384\ \(0\)\
\-\ consumptive\\:\\ 0\\.027634853993625384\ \(0\)\
\-\ birth\\:\\ 0\\.025742872869305104\ \(0\)\
\-\ strawberry\\:\\ 0\\.025461978819456277\ \(0\)\
\-\ explanations\\:\\ 0\\.025461978819456277\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.024561353473289776\ \(0\)\
\-\ inhibit\\:\\ 0\\.0241909283238194\ \(0\)\
\-\ triggering\\:\\ 0\\.0241909283238194\ \(0\)\
\-\ sarcoma\\:\\ 0\\.023855066644954497\ \(0\)\
\-\ extraosseous\\:\\ 0\\.02328910364528717\ \(0\)\
\-\ inconspicuous\\:\\ 0\\.02328910364528717\ \(0\)\
\-\ involute\\:\\ 0\\.02328910364528717\ \(0\)\
\-\ blanching\\:\\ 0\\.02328910364528717\ \(0\)\
\-\ problematic\\:\\ 0\\.02328910364528717\ \(0\)\
\-\ apoptosis\\:\\ 0\\.02328910364528717\ \(0\)\
\-\ appearance\\:\\ 0\\.022983447430106347\ \(0\)\
\-\ deeper\\:\\ 0\\.02201805314965029\ \(0\)\
\-\ interferon\\:\\ 0\\.02201805314965029\ \(0\)\
\-\ vasoconstriction\\:\\ 0\\.02201805314965029\ \(0\)\
\-\ appear\\:\\ 0\\.021927262884779194\ \(0\)\
\-\ cells\\:\\ 0\\.021482424414733525\ \(0\)\
\-\ malformation\\:\\ 0\\.02136894452982056\ \(0\)\
\-\ plexiform\\:\\ 0\\.02074700265401341\ \(0\)\
\-\ twins\\:\\ 0\\.02074700265401341\ \(0\)\
\-\ macules\\:\\ 0\\.02074700265401341\ \(0\)\
\-\ kinase\\:\\ 0\\.02074700265401341\ \(0\)\
\-\ whites\\:\\ 0\\.020416718905869755\ \(0\)\
\-\ threatening\\:\\ 0\\.020416718905869755\ \(0\)\
\-\ depth\\:\\ 0\\.02011794091275275\ \(0\)\
\-\ action\\:\\ 0\\.02011794091275275\ \(0\)\
\-\ intralesional\\:\\ 0\\.019845177975481184\ \(0\)\
\-\ undifferentiated\\:\\ 0\\.019845177975481184\ \(0\)\
\-\ pathway\\:\\ 0\\.019845177975481184\ \(0\)\
\-\ coagulopathy\\:\\ 0\\.019594260396567274\ \(0\)\
\-\ they\\:\\ 0\\.01930373747013985\ \(0\)\
\-\ ewings\\:\\ 0\\.018943353296948955\ \(0\)\
\-\ intensely\\:\\ 0\\.018574127479844306\ \(0\)\
\-\ are\\:\\ 0\\.018258211168175574\ \(0\)\
\-\ telangiectasia\\:\\ 0\\.01809089650859898\ \(0\)\
\-\ vincristine\\:\\ 0\\.01809089650859898\ \(0\)\
\-\ dermal\\:\\ 0\\.017945065738583642\ \(0\)\
\-\ alpha\\:\\ 0\\.017945065738583642\ \(0\)\
\-\ natural\\:\\ 0\\.017805718520493254\ \(0\)\
\-\ begin\\:\\ 0\\.017805718520493254\ \(0\)\
\-\ depends\\:\\ 0\\.017805718520493254\ \(0\)\
\-\ blue\\:\\ 0\\.017672302801312077\ \(0\)\
\-\ regression\\:\\ 0\\.017421385222398167\ \(0\)\
\-\ unclear\\:\\ 0\\.017079067692727348\ \(0\)\
\-\ lesion\\:\\ 0\\.016368857924769168\ \(0\)\
\-\ corticosteroids\\:\\ 0\\.016315362104458535\ \(0\)\
\-\ proliferation\\:\\ 0\\.016150334726761292\ \(0\)\
\-\ treated\\:\\ 0\\.016036682357892535\ \(0\)\
\-\ infants\\:\\ 0\\.015565425775098557\ \(0\)\
\-\ erythematous\\:\\ 0\\.015565425775098557\ \(0\)\
\-\ rhabdomyosarcoma\\:\\ 0\\.015072680999166229\ \(0\)\
\-\ childhood\\:\\ 0\\.015072680999166229\ \(0\)\
\-\ include\\:\\ 0\\.015029175473544116\ \(0\)\
\-\ occurring\\:\\ 0\\.014960712088187925\ \(0\)\
\-\ females\\:\\ 0\\.014906192518558242\ \(0\)\
\-\ conservatively\\:\\ 0\\.014906192518558242\ \(0\)\
\-\ neurofibroma\\:\\ 0\\.014852604953168584\ \(0\)\
\-\ ulcer\\:\\ 0\\.0147481020683172\ \(0\)\
\-\ premature\\:\\ 0\\.01459760294861074\ \(0\)\
\-\ fissure\\:\\ 0\\.014361792850687267\ \(0\)\
\-\ superficial\\:\\ 0\\.014316687090649339\ \(0\)\
\-\ half\\:\\ 0\\.01414248693028943\ \(0\)\
\-\ arteriovenous\\:\\ 0\\.014058887409655696\ \(0\)\
\-\ common\\:\\ 0\\.014020484087500921\ \(0\)\
\-\ mechanism\\:\\ 0\\.013782689078902507\ \(0\)\
\-\ protein\\:\\ 0\\.013745146160260764\ \(0\)\
\-\ enlarging\\:\\ 0\\.013635142022921362\ \(0\)\
\-\ neoplasms\\:\\ 0\\.013635142022921362\ \(0\)\
\-\ lobulated\\:\\ 0\\.01345996817215504\ \(0\)\
\-\ more\\:\\ 0\\.013399224509794146\ \(0\)\
\-\ develop\\:\\ 0\\.01335937784440739\ \(0\)\
\-\ \\/\\:\\ 0\\.013230089573140778\ \(0\)\
\-\ interval\\:\\ 0\\.013136506616558704\ \(0\)\
\-\ baby\\:\\ 0\\.01304563659501246\ \(0\)\
\-\ options\\:\\ 0\\.013015922664120475\ \(0\)\
\-\ resolved\\:\\ 0\\.012986487741393703\ \(0\)\
\-\ potential\\:\\ 0\\.012899805824997121\ \(0\)\
\-\ observed\\:\\ 0\\.012843321481728537\ \(0\)\
\-\ veins\\:\\ 0\\.012815456442803\ \(0\)\
\-\ vital\\:\\ 0\\.012815456442803\ \(0\)\
\-\ \\,\\:\\ 0\\.012729313425577777\ \(0\)\
\-\ \\;\\:\\ 0\\.012698565444843848\ \(0\)\
\-\ short\\:\\ 0\\.012627042887725556\ \(0\)\
\-\ degree\\:\\ 0\\.012549636578664829\ \(0\)\
\-\ \\%\\:\\ 0\\.012497310553893465\ \(0\)\
\-\ most\\:\\ 0\\.01236887236193151\ \(0\)\
\-\ small\\:\\ 0\\.01234216479235811\ \(0\)\
\-\ having\\:\\ 0\\.012304605942773494\ \(0\)\
\-\ decrease\\:\\ 0\\.012257817070620904\ \(0\)\
\-\ as\\:\\ 0\\.012155901309349165\ \(0\)\
\-\ can\\:\\ 0\\.012151864278802944\ \(0\)\
\-\ generally\\:\\ 0\\.012055501957336982\ \(0\)\
\-\ clinically\\:\\ 0\\.011744872168483595\ \(0\)\
\-\ 60\\:\\ 0\\.011686276140232333\ \(0\)\
\-\ life\\:\\ 0\\.011686276140232333\ \(0\)\
\-\ growth\\:\\ 0\\.0116478119001326\ \(0\)\
\-\ bleeding\\:\\ 0\\.011628755329360243\ \(0\)\
\-\ absent\\:\\ 0\\.011609813904733401\ \(0\)\
\-\ children\\:\\ 0\\.011572270986091659\ \(0\)\
\-\ stage\\:\\ 0\\.011426440216076321\ \(0\)\
\-\ characteristic\\:\\ 0\\.011338625055488001\ \(0\)\
\-\ mass\\:\\ 0\\.011176749281638539\ \(0\)\
\-\ formation\\:\\ 0\\.011057214398971671\ \(0\)\
\-\ line\\:\\ 0\\.011010073717578128\ \(0\)\
\-\ prominent\\:\\ 0\\.01099451638421722\ \(0\)\
\-\ 12\\:\\ 0\\.010963631442389597\ \(0\)\
\-\ upon\\:\\ 0\\.010948302334884294\ \(0\)\
\-\ shoulder\\:\\ 0\\.010798998106077854\ \(0\)\
\-\ vessels\\:\\ 0\\.010784451461700102\ \(0\)\
\-\ typical\\:\\ 0\\.010741212207366763\ \(0\)\
\-\ 15\\:\\ 0\\.01068447226491028\ \(0\)\
\-\ complications\\:\\ 0\\.010614961739849708\ \(0\)\
\-\ marked\\:\\ 0\\.010454167713556447\ \(0\)\
\-\ process\\:\\ 0\\.010313684905437976\ \(0\)\
\-\ structures\\:\\ 0\\.010313684905437976\ \(0\)\
\-\ skin\\:\\ 0\\.010288805439620621\ \(0\)\
\-\ course\\:\\ 0\\.010108249039045896\ \(0\)\
\-\ compression\\:\\ 0\\.010027421085579706\ \(0\)\
\-\ involvement\\:\\ 0\\.009817989519209456\ \(0\)\
\-\ venous\\:\\ 0\\.009723465888580342\ \(0\)\
\-\ or\\:\\ 0\\.009418709237903207\ \(0\)\
\-\ girl\\:\\ 0\\.009418111068933536\ \(0\)\
\-\ involving\\:\\ 0\\.00939939581192255\ \(0\)\
\-\ benign\\:\\ 0\\.009244671996969283\ \(0\)\
\-\ 10\\:\\ 0\\.009030169994817901\ \(0\)\
\-\ first\\:\\ 0\\.008988976284595147\ \(0\)\
\-\ size\\:\\ 0\\.008980802104635647\ \(0\)\
\-\ by\\:\\ 0\\.008920820709999215\ \(0\)\
\-\ flow\\:\\ 0\\.008852833469775912\ \(0\)\
\-\ vascular\\:\\ 0\\.00878308234458839\ \(0\)\
\-\ while\\:\\ 0\\.008428367523048003\ \(0\)\
\-\ enhancing\\:\\ 0\\.008401108253557239\ \(0\)\
\-\ will\\:\\ 0\\.008380818239433046\ \(0\)\
\-\ such\\:\\ 0\\.008374083980692327\ \(0\)\
\-\ clinical\\:\\ 0\\.008242350470426344\ \(0\)\
\-\ age\\:\\ 0\\.008153323904527606\ \(0\)\
\-\ month\\:\\ 0\\.008036409218810688\ \(0\)\
\-\ years\\:\\ 0\\.007865965946766402\ \(0\)\
\-\ 5\\:\\ 0\\.007837493487285779\ \(0\)\
\-\ two\\:\\ 0\\.0076718847574169455\ \(0\)\
\-\ all\\:\\ 0\\.007576562662794014\ \(0\)\
\-\ secondary\\:\\ 0\\.007489122152065227\ \(0\)\
\-\ high\\:\\ 0\\.007330865395225127\ \(0\)\
\-\ months\\:\\ 0\\.007316430390877954\ \(0\)\
\-\ been\\:\\ 0\\.00728775827418179\ \(0\)\
\-\ at\\:\\ 0\\.007258703152549423\ \(0\)\
\-\ these\\:\\ 0\\.006971299974789467\ \(0\)\
\-\ tumor\\:\\ 0\\.006245242324798781\ \(0\)\
\-\ a\\:\\ 0\\.0062162978341473545\ \(0\)\
\-\ other\\:\\ 0\\.00617441551317382\ \(0\)\
\-\ demonstrate\\:\\ 0\\.006164426775338685\ \(0\)\
\-\ have\\:\\ 0\\.005800746327163297\ \(0\)\
\-\ treatment\\:\\ 0\\.005421996738560774\ \(0\)\
\-\ also\\:\\ 0\\.005280939165110192\ \(0\)\
\-\ the\\:\\ 0\\.005200600051547052\ \(0\)\
\-\ of\\:\\ 0\\.005113019470758113\ \(0\)\
\-\ has\\:\\ 0\\.005030407431016545\ \(0\)\
\-\ \\(\\:\\ 0\\.004528913644162135\ \(0\)\
\-\ \\)\\:\\ 0\\.004473590546164922\ \(0\)\
\-\ be\\:\\ 0\\.0041308988192599655\ \(0\)\
\-\ to\\:\\ 0\\.004016314499463821\ \(0\)\
\-\ in\\:\\ 0\\.003962983355550987\ \(0\)\
\-\ and\\:\\ 0\\.003950040878136455\ \(0\)\
\-\ history\\:\\ 0\\.0036997320931256533\ \(0\)\
\-\ is\\:\\ 0\\.0035253340337600353\ \(0\)\
\-\ was\\:\\ 0\\.0030980486589770747\ \(0\)\
\-\ this\\:\\ 0\\.0030129693207339592\ \(0\)\
\-\ right\\:\\ 0\\.002826431690001306\ \(0\)\
\-\ old\\:\\ 0\\.002742741682953776\ \(0\)\
\-\ patient\\:\\ 0\\.0026852411627472975\ \(0\)\
\-\ with\\:\\ 0\\.0025674897574583955\ \(0\)\
\-\ for\\:\\ 0\\.0022856054816386053\ \(0\)\
\-\ \\.\\:\\ 0\\.0022256762443477285\ \(0\)\
